Doerring, M.D., former FDA medical officer in the division of psychiatry and the founder and CEO of TaperClinic, he shares ...
Each year, millions of people in America are prescribed a medicine for acute pain.Now, for the first time in over 20 years, ...
According to a Vertex spokesperson, the drug is seeing strong initial market adoption, with growing payer coverage and ...
FDA approval of a novel non-opioid analgesic will hopefully address the needs of many patients with acute pain and improve ...
The FDA approves a new non-opioid pain pill, Journavx, to treat acute pain in adults. It's a first-generation non-addictive ...
The non-profit Institute for Clinical and Economic Review has issued a lukewarm final evidence report on Vertex Pharmaceuticals' (NASDAQ:VRTX) non-opioid pain medicine Journavx (suzetrigine).
“The FDA approval of suzetrigine (Journavx) opens the door to a new class of oral systemic medications for patients who suffer from acute pain, including pain after surgery,” says Dr. Edward ...
After its January FDA approval for moderate to severe acute pain in adults, the company priced Journavx at $15.50 per 50mg tablet.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback